
Paroxysmal nocturnal haemoglobinuria (PNH) Program in Pharmaceutical Benefits Scheme (PBS) 012-22022230

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines the PBS subsidised eculizumab and ravulizumab for
patients with PNH.

PNH and listing dates

Paroxysmal nocturnal haemoglobinuria is a rare acquired, life
threatening disease of the blood that causes red blood cells to break
apart.

Listing dates:

-   eculizumab - 1 March 2022
-   ravulizumab - 1 March 2022

See Written Authority Required Drugs for more information

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
restriction and item codes, and the PBS and Services Australia websites.

Related links

Processing and National Demand Allocation (PaNDA)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA)

Process telephone authority approval application

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
